ReviewJournal of physiology and biochemistry2023
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Review in Journal of physiology and biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Short-Term Impact of Endoscopic Gastric Remodeling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Obesity surgery · 2026Pooled it
- Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.Journal of gastroenterology and hepatology · 2026Article
- SIRT3-mediated mitochondrial fatty acid oxidation protects against hepatic lipid deposition in fatty liver hemorrhagic syndrome.Poultry science · 2026Article
- Paris Saponin VII Inhibits Ferroptosis through USP7/SLC7A11 to Alleviate Metabolic-associated Fatty Liver Disease in Rats.Applied biochemistry and biotechnology · 2026Article
- Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.Journal of clinical pharmacology · 2026Article
- Positive feedback between histone H4K16 lactylation and glycolysis promotes MAFLD progression.Hepatology international · 2026Article
- Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2026Review
- Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Phytochemical Profiling and Pharmacoinformatics Reveal Proliverenol fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Nonlinear associations of remnant cholesterol/high-density lipoprotein cholesterol ratio with the risk of metabolic-associated fatty liver disease: a cross-sectional study.BMC gastroenterology · 2026Article
- MAFLD: a ferroptotic disease.Trends in molecular medicine · 2026Review
- Therapeutic Potential of Saikosaponins in MASLD and Cross-Organ Protection: A Research Update.Food science & nutrition · 2026Review
- Preoperative Metabolic Risk Factors and Outcomes in Living Donor Liver Transplant in HBV Recipients.Journal of clinical medicine · 2026Article
- Integrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis.Frontiers in immunology · 2026Article
- Eating behaviors and liver health in metabolic dysfunction-associated fatty liver disease: the serial mediating roles of Mediterranean diet adherence and adiposity.Frontiers in nutrition · 2026Article
- Plant metabolites targeting the AMPK pathway: advances in the mechanisms of action in the context of MAFLD.Frontiers in pharmacology · 2026Review
- Context-dependent Activities of Mitrephorone Link Lipid Redirection, Anti-inflammatory Action, and Ferroptosis Control to Hepatocyte Protection.Theranostics · 2026Article
- Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial.Nutrition & metabolism · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is nowadays considered the liver manifestation of metabolic syndrome. Its prevalence is increasing worldwide in parallel to the epidemic of diabetes and obesity. MAFLD includes a wide spectrum of liver injury including simple steatosis and non-alcoholic steatohepatitis (NASH) that may lead to serious complications such as liver cirrhosis and liver cancer. The complexity of its pathophysiology and the intricate mechanisms underlying disease progression explains the huge variety of molecules targeting diverse biological mechanisms that have been tested in preclinical and clinical settings in the last two decades. Thanks to the large number of clinical trials of the last few years, most of them still ongoing, the pharmacotherapy scenario of MAFLD is rapidly evolving. The three major components of MAFLD, steatosis, inflammation, and fibrosis seem to be safely targeted with different agents at least in a large proportion of patients. Likely, in the next few years more than one drug will be approved for the treatment of MAFLD at different disease stages. The aim of this review is to synthesize the characteristics and the results of the most advanced clinical trials for the treatment of NASH to evaluate the recent advances of pharmacotherapy in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.